Hughes, T E <br/><br/>
Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women.  [electronic resource] 

 -  Obesity (Silver Spring, Md.)  Sep 2013 
 - 1782-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1930-739X 
<br/><br/><label>Standard No.: </label>10.1002/oby.20356  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3-Hydroxybutyric Acid--blood<br/>Adiponectin--blood<br/>Aminopeptidases--antagonists & inhibitors<br/>Anti-Obesity Agents--adverse effects<br/>Aspergillus--chemistry<br/>Biological Products--adverse effects<br/>Blood Glucose--metabolism<br/>Blood Pressure<br/>C-Reactive Protein--metabolism<br/>Cholesterol, LDL--blood<br/>Cyclohexanes--adverse effects<br/>Double-Blind Method<br/>Fatty Acids, Unsaturated--adverse effects<br/>Female<br/>Fibroblast Growth Factors--blood<br/>Glycoproteins--antagonists & inhibitors<br/>Humans<br/>Hunger--drug effects<br/>Infusions, Intravenous<br/>Leptin--blood<br/>Lipids--blood<br/>Methionyl Aminopeptidases<br/>Middle Aged<br/>Obesity--blood<br/>Sesquiterpenes--adverse effects<br/>Triglycerides--blood<br/>Weight Loss--drug effects